Swiss drug giant Novartis has extended its partnership with MorphoSys, a German biotechnology firm, saying it will pay at least US$600 million over 10 years as the price of working with the smaller company to help it discover and develop antibody-based medicines. If Munich-based MorphoSys meets milestones for clinical development and market approval, the payments could exceed $1 billion, the companies said on 2 December. Novartis will gain almost exclusive access to the smaller firm's libraries of human antibodies, copies of which will be transferred to Novartis research sites.
Rights and permissions
About this article
Cite this article
Euro tie-up. Nature 450, 935 (2007). https://doi.org/10.1038/450935a
Published:
Issue Date:
DOI: https://doi.org/10.1038/450935a